Address
Contact
Tel: 0351 4561 0 Fax: 0351 4561 211 ssw.info@gsk.com www.glaxosmithkline.deContact person
Dr. Jacqueline SchönfelderOffer
Development, manufacture and sales of pharmaceutical products, vaccines
- GSK Biologicals in Dresden is a subsidiary of GSK Germany and
functionally supports the international sector of GSK Biologicals
- GSK Biologicals markets over 30 vaccines worldwide against
diseases as influenza, polio, diphtheria, tetanus, whooping cough,
hepatitis A / B, meningitis, measles, rubella, mumps, chickenpox,
typhoid, rotavirus, cervical cancer and pneumococcal disease
- Over 20 vaccines are in clinical development
- GSK Biologicals employs more than 9.500 people worldwide, thereof
over 1.600 scientists
- 2009 GSK Biologicals sold 1,4 billion vaccine doses amounting to
3,7 billion £ and increased his sales by 30 percent
- GSK Biologicals is among the primary suppliers of international
organisations like UNICEF and gets involved with the struggle
against the world’s main diseases identified by the WHO: AIDS,
malaria, tuberculosis
- Vaccines to some of the most disadvantaged regions of the world
are provided by GSK Biologicals at preferential prices – almost
80 percent of the vaccine doses were distributed to these regions
in 2009 (excl. pandemic flu vaccines)
Right in the centre of Dresden GlaxoSmithKline (GSK) Biologicals is
located and produces flu vaccines for the global market: The seasonal
flu vaccine Fluarix® (inside Germany distributed as Influsplit SSW®
) is delivered into more than 70 countries. The factory was founded in 1911 and has been located at the Zirkusstraße since 1924. At present
more than 600 people including apprentices work at this traditional site. As specialist for the development and production of flu vaccines the site was acquired by SmithKline Beecham in 1992 and has been continuously extended since then. The annual production capacity amounts to 70 million vaccine doses. During the last years GSK Biologicals, Dresden could prove its expertise by developing and producing the pandemic H1N1 flu vaccine in time. The improvement and development of the seasonal flu vaccine are currently given priority. Besides the seasonal production, the Dresden site’s portfolio is completed by the filling and packaging of additional liquid vaccines. The current intention to invest comprehensively in the modernization of packaging and production facilities also illustrates the site’s importance within the global GSK network.